Cell and Gene Therapies Manufacturing Challenges and Integrated Good Manufacturing Practices Solutions: A Lifecycle Perspective.

Abstract

Cell and gene therapies (CGTs) are revolutionizing modern medicine; however, making these advanced medicines scalable and readily available to commercial manufacturers worldwide is a major challenge. The number of approved CGT products continues to rise each year; however, many challenges remain, including donor-to-donor biological variability, contamination risks in aseptic processing, vector production issues, concerns about genomic safety, and cold-chain instability. These problems negatively impact reproducibility, regulatory compliance, product quality, and patient access. The current literature in this area often focuses on individual aspects of the process without providing an integrated view of the entire CGT product life cycle within the framework of good manufacturing practice (GMP). This review covers the manufacturing issues in the CGT life cycle, ranging from development to commercial manufacturing, and places them in a changing global regulatory landscape. A comparative review of the regulatory scenario of the Food and Drug Administration, European Medicines Agency, Central Drugs Standard Control Organization, and other global regulatory authorities, highlighting harmonization efforts and regulatory assistance for mass commercialization. The review also emphasizes post-approval change management protocols and product life cycle management documents as approaches to reduce the risk of comparability issues in process scale-up and technology transfer, in line with the International Council for Harmonization guideline Q12. In addition, the review covers new manufacturing paradigms, such as decentralized point-of-care manufacturing, Quality by Design (QbD), automation, closed-system processing, and advanced risk-based control strategies. Looking forward, AI-powered digital twins, continuous process verification, modular "GMP-in-a-box," allogeneic universal platforms, predictive cold chains, and sustainable green GMP are explored as routes to robust, scalable, and patient-centered CGT manufacturing.